Cidara Therapeutics, Inc.
CDTX
$20.69
$1.256.40%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -242.85% | 19.95% | -76.99% | -195.12% | 31.72% |
| Total Depreciation and Amortization | 49.15% | 44.44% | 129.25% | 216.39% | -17.48% |
| Total Amortization of Deferred Charges | -79.22% | 102.33% | 32.50% | -180.42% | -- |
| Total Other Non-Cash Items | -4.92% | -20.96% | -31.11% | 5.98% | -6.42% |
| Change in Net Operating Assets | 142.27% | -887.40% | -122.37% | 277.29% | -963.44% |
| Cash from Operations | -224.33% | -82.54% | -1,800.45% | -15.32% | 21.22% |
| Capital Expenditure | 74.46% | 8.63% | -49.32% | -239.06% | -327.97% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 74.46% | 8.63% | -49.32% | -239.06% | -327.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 86.52% | 96.63% | -- |
| Issuance of Common Stock | 274.48% | -99.97% | -99.97% | -99.97% | 1,011.13% |
| Repurchase of Common Stock | 44.06% | 44.06% | 85.06% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 99.44% | 99.44% | -- |
| Cash from Financing | 276.89% | -101.00% | -100.32% | -101.34% | 2,832.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 722.05% | -1,184.82% | -184.22% | -289.47% | 110.31% |